Page 829 - Read Online

Page 8 of 15 Bhangui et al. Hepatoma Res 2020;6:71 I http://dx.doi.org/10.20517/2394-5079.2020.67

Figure 3. Overall survival post hepatocellular carcinoma recurrence in 100 patients

Table 3. Cox regression analysis for survival post HCC recurrence
Univariate analysis Multivariate analysis
Parameters
Hazard ratio 95%CI P value Hazard ratio 95%CI P value
Age at the time of recurrence 1.02 0.98-1.05 0.34
Gender - Male 0.90 0.46-1.78 0.77
HCC within vs. outside UCSF criteria at the 1.06 0.66-1.70 082
time of LDLT
Type of recurrence: recurrence at single vs. 1.70 1.06-2.73 0.029 1.831 1.009-3.321 0.047
multiple sites
Tumour burden: single nodule vs. multiple 2.23 1.13-4.40 0.022 1.462 0.719-2.970 0.294
nodules
Intrahepatic only vs. extrahepatic or 0.58 0.29-1.13 0.11
Intrahepatic plus extrahepatic metastases
Alpha fetoprotein at the time of recurrence 2.59 1.42-4.71 0.002 2.075 1.121-3.841 0.020
AFP < 200 vs. > 200 ng/mL
Time to HCC recurrence: > 1 year after LDLT 2.49 1.56-3.98 0.001 2.381 1.325-4.276 0.004
vs. within 1 year of LDLT

HCC: hepatocellular carcinoma; LDLT: living donor liver transplantation; UCSF: University of California, San Francisco; mTORi:
mammalian target of rapamycin inhibitor